{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:43:42Z","timestamp":1792881822392,"version":"4.5.0"},"reference-count":111,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory disorder with two main subtypes: ulcerative colitis (UC) and Crohn\u2019s disease (CD). The pathogenesis involves genetic predisposition, dysbiosis, and immune dysregulation. Complications include perianal lesions, strictures, fistulas, perforations, and an increased risk of colon cancer. Clinical classification ranges from mild to fulminant and recurrent disease, with common symptoms such as abdominal discomfort, rectal bleeding, diarrhea, and weight loss. Extraintestinal manifestations include arthritis, erythema nodosum, pyoderma gangrenosum, and uveitis. Conventional treatments using aminosalicylates, corticosteroids, and immunomodulators have limitations. Biologics, introduced in the 1990s, offer improved efficacy and specificity, targeting factors like TNF-\u03b1, integrins, and cytokines. Monoclonal antibodies play a crucial role in IBD management, aiming to reduce relapses, hospitalizations, and surgeries. In conclusion, this review is aimed at summarizing the latest knowledge, advantages, and drawbacks of IBD therapies, such as small molecules, biologics, and monoclonal antibodies, to provide a basis for further research in the IBD field.<\/jats:p>","DOI":"10.3390\/pharmaceutics16091185","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T03:04:18Z","timestamp":1725851058000},"page":"1185","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9994-6968","authenticated-orcid":false,"given":"Annalisa","family":"Di Rienzo","sequence":"first","affiliation":[{"name":"Department of Pharmacy, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Marinelli","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9381-7196","authenticated-orcid":false,"given":"Marilisa Pia","family":"Dimmito","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora Chiara","family":"Toto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3042-2234","authenticated-orcid":false,"given":"Antonio","family":"Di Stefano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-0443","authenticated-orcid":false,"given":"Ivana","family":"Cacciatore","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/ecco-jcc\/jjac177","article-title":"Increasing Incidence of Inflammatory Bowel Disease, with Greatest Change Among the Elderly: A Nationwide Study in Finland, 2000\u20132020","volume":"17","author":"Kontola","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn\u2019s disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Honap","year":"2023","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S2468-1253(23)00011-0","article-title":"Inflammation and malnutrition in inflammatory bowel disease","volume":"8","author":"Massironi","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative Colitis in Adults: A Review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/gutjnl-2020-322129","article-title":"Emerging treatment options for extraintestinal manifestations in IBD","volume":"70","author":"Greuter","year":"2021","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of biologics and biosimilars in inflammatory bowel disease: Current trends and future perspectives","volume":"11","author":"Rawla","year":"2018","journal-title":"J. Inflamm. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6888","DOI":"10.3748\/wjg.v28.i48.6888","article-title":"Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease","volume":"28","author":"Xu","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Faris, A., Cacciatore, I., Ibrahim, I.M., Al Mughram, M.H., Hadni, H., Tabti, K., and Elhallaoui, M. (2023). In silico computational drug discovery: A Monte Carlo approach for developing a novel JAK3 inhibitors. J. Biomol. Struct. Dyn., 1\u201323.","DOI":"10.1080\/07391102.2023.2270709"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.gastro.2006.04.020","article-title":"Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection","volume":"131","author":"Velcich","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1073\/pnas.0803124105","article-title":"The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria","volume":"105","author":"Johansson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41575-022-00675-x","article-title":"The role of goblet cells and mucus in intestinal homeostasis","volume":"19","author":"Gustafsson","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41586-019-0992-y","article-title":"Colonic epithelial cell diversity in health and inflammatory bowel disease","volume":"567","author":"Parikh","year":"2019","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Stolfi, C., Maresca, C., Monteleone, G., and Laudisi, F. (2022). Implication of Intestinal Barrier Dysfunction in Gut Dysbiosis and Diseases. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020289"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.tem.2022.01.002","article-title":"Gut barrier disruption and chronic disease","volume":"33","author":"Martel","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Eckmann","year":"2012","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ruder, B., Atreya, R., and Becker, C. (2019). Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20081887"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17562848211059954","DOI":"10.1177\/17562848211059954","article-title":"Tumour necrosis factor inhibitors in inflammatory bowel disease: The story continues","volume":"14","author":"Sandborn","year":"2021","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_21","first-page":"CD003715","article-title":"Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s disease","volume":"9","author":"Akobeng","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MIB.0000000000001023","article-title":"Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn\u2019s Disease: A Bayesian Network Meta-analysis","volume":"23","author":"Coward","year":"2017","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Khare, V., Krnjic, A., Frick, A., Gmainer, C., Asboth, M., Jimenez, K., Lang, M., Baumgartner, M., Evstatiev, R., and Gasche, C. (2019). Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-39401-0"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41591-023-02217-7","article-title":"Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease","volume":"29","author":"Mehta","year":"2023","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ibd.20099","article-title":"5-Aminosalicylates and renal function in inflammatory bowel disease: A systematic review","volume":"13","author":"Gisbert","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Becker, H.E.F., Demers, K., Derijks, L.J.J., Jonkers, D.M.A.E., and Penders, J. (2023). Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1107976"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3399\/bjgp18X699341","article-title":"Using corticosteroids appropriately in inflammatory bowel disease: A guide for primary care","volume":"68","author":"Barrett","year":"2018","journal-title":"Br. J. Gen. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bruscoli, S., Febo, M., Riccardi, C., and Migliorati, G. (2021). Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.691480"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Manguso, F., Bennato, R., Lombardi, G., Riccio, E., Costantino, G., and Fries, W. (2016). Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166455"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/21678707.2014.968125","article-title":"Beclomethasone dipropionate for the treatment of ulcerative colitis","volume":"3","author":"Gabbani","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/gutjnl-2015-310874","article-title":"Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism","volume":"66","author":"Oancea","year":"2017","journal-title":"Gut"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/ecco-jcc\/jjw091","article-title":"Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases","volume":"10","author":"Atreya","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100271","DOI":"10.1016\/j.eclinm.2020.100271","article-title":"Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials","volume":"20","author":"Nielsen","year":"2020","journal-title":"eClinicalMedicine"},{"key":"ref_34","first-page":"43","article-title":"The Current Role of Methotrexate in Patients with Inflammatory Bowel Disease","volume":"16","author":"Rosh","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21037\/tgh.2019.08.08","article-title":"A novel player: Cyclosporine therapy in the management of inflammatory bowel disease","volume":"4","author":"Weissman","year":"2019","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ibd\/izz068","article-title":"Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review","volume":"26","author":"Wu","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Shimizu, H., Fujii, T., Kinoshita, K., Kawamoto, A., Hibiya, S., Takenaka, K., Saito, E., Nagahori, M., Ohtsuka, K., and Watanabe, M. (2021). Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-02043-6"},{"key":"ref_38","first-page":"e10621","article-title":"Biologics Targeting in the Treatment of Inflammatory Bowel Disease: A Conundrum","volume":"12","author":"Rehman","year":"2020","journal-title":"Cureus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease","volume":"20","author":"Neurath","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9300","DOI":"10.3748\/wjg.v22.i42.9300","article-title":"Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases","volume":"22","author":"Billmeier","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Avedillo-Salas, A., Corral-Cativiela, S., Fanlo-Villacampa, A., and Vicente-Romero, J. (2023). The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate-Severe Crohn\u2019s Disease: A Systematic Review. Pharmaceuticals, 16.","DOI":"10.3390\/ph16111581"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/jbcpp-2018-0036","article-title":"Immune response and inflammatory pathway of ulcerative colitis","volume":"30","author":"Chatuphonprasert","year":"2018","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1053\/j.gastro.2006.03.022","article-title":"Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions","volume":"130","author":"Begue","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00054725-199811000-00014","article-title":"Infliximab approved for use in Crohn\u2019s disease: A report on the FDA GI Advisory Committee conference","volume":"4","author":"Kornbluth","year":"1998","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2125.2010.03760.x","article-title":"Appropriate infliximab infusion dosage and monitoring: Results of a panel meeting of rheumatologists, dermatologists and gastroenterologists","volume":"71","author":"Driessen","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","article-title":"Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease","volume":"50","author":"Peppelenbosch","year":"2002","journal-title":"Gut"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease","volume":"124","author":"Braat","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2040622319838443","DOI":"10.1177\/2040622319838443","article-title":"Infliximab in inflammatory bowel disease","volume":"10","author":"Papamichael","year":"2019","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Vaisman-Mentesh, A., Rosenstein, S., Yavzori, M., Dror, Y., Fudim, E., Ungar, B., Kopylov, U., Picard, O., Kigel, A., and Ben-Horin, S. (2019). Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment with TNF\u03b1 Antagonists. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02921"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/1744666X.2018.1468753","article-title":"Immunogenicity of biologic therapies: Causes and consequences","volume":"14","author":"Boehncke","year":"2018","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_54","unstructured":"(2023, December 01). FDA Approves Zymfentra (infliximab-dyyb) Subcutaneous Formulation for the Treatment of People with Inflammatory Bowel Disease. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-zymfentra-infliximab-dyyb-subcutaneous-formulation-inflammatory-bowel-6122.html."},{"key":"ref_55","unstructured":"(2023, December 03). Humira (Adalimumab): Prescribing Information. Available online: http:\/\/www.rxabbvie.com\/pdf\/humira.pdf."},{"key":"ref_56","unstructured":"European Medicines Agency (EMA) (2023, December 05). Humira Summary of Product Characteristics, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40001-022-00817-6","article-title":"Adalimumab for induction of remission in patients with Crohn\u2019s disease: A systematic review and meta-analysis","volume":"27","author":"Yin","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1756284818821266","DOI":"10.1177\/1756284818821266","article-title":"Golimumab in the treatment of ulcerative colitis","volume":"12","author":"Cunningham","year":"2019","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_61","unstructured":"US Food and Drug Administration (FDA) (2023, December 05). Cimzia Prescribing Information, Available online: https:\/\/www.cimzia.com\/themes\/custom\/cimzia\/docs\/CIMZIA_full_prescribing_information.pdf."},{"key":"ref_62","first-page":"1819","article-title":"FDA approves Cimzia to treat Crohn\u2019s disease","volume":"134","author":"Lang","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1756283X11413315","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"4","author":"Schreiber","year":"2011","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_64","first-page":"CD013747","article-title":"Certolizumab pegol for maintenance of medically induced remission in Crohn\u2019s disease","volume":"6","author":"Okabayashi","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.biophys.31.101101.140922","article-title":"Conformational regulation of integrin structure and function","volume":"31","author":"Shimaoka","year":"2002","journal-title":"Annu. Rev. Biophys. Biomol. Struct."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S653","DOI":"10.1093\/ecco-jcc\/jjy060","article-title":"Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease","volume":"12","author":"Lamb","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/med.21601","article-title":"The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies","volume":"40","author":"Dotan","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/CEG.S293272","article-title":"Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives","volume":"14","author":"Gubatan","year":"2021","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_69","first-page":"CD006097","article-title":"Natalizumab for induction of remission in Crohn\u2019s disease","volume":"8","author":"Nelson","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease","volume":"353","author":"Sciot","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_71","unstructured":"US Food and Drug Administration (2024, May 18). FDA Drug Safety Communication: New Risk Factor for Progressive Multifocal Leukoencephalopathy (PML) Associated with Tysabri (Natalizumab), Available online: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm288186.htm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/flgastro-2018-101054","article-title":"Recent advances in monoclonal antibody therapy in IBD: Practical issues","volume":"10","author":"Tamilarasan","year":"2019","journal-title":"Frontline Gastroenterol."},{"key":"ref_73","unstructured":"(2023, December 06). U.S. FDA Approves Subcutaneous Administration of Takeda\u2019s Entyvio (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis. Entyvio (Vedolizumab) FDA Approval History-Drugs.com. Available online: https:\/\/www.drugs.com\/newdrugs\/u-s-fda-approves-subcutaneous-administration-takeda-s-entyvio-vedolizumab-maintenance-therapy-6099.html."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(21)00298-3","article-title":"Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): A phase 3, randomised, controlled trial","volume":"7","author":"Hart","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2018.12.002","article-title":"IL-23 in inflammatory bowel diseases and colon cancer","volume":"45","author":"Neurath","year":"2019","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"ii64","DOI":"10.1093\/ecco-jcc\/jjab185","article-title":"Blockade of IL-23: What is in the Pipeline?","volume":"16","author":"Parigi","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_79","unstructured":"European Medicines Agency (2023, December 04). Stelara, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/ibd\/izae096","article-title":"Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results from the LUCENT-3 Open-Label Extension Study","volume":"30","author":"Sands","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_83","unstructured":"European Medicines Agency (2024, July 24). Omvoh, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omvoh-epar-product-information_en.pdf."},{"key":"ref_84","first-page":"1329","article-title":"Briakinumab for treatment of Crohn\u2019s disease: Results of a randomized trial","volume":"21","author":"Panaccione","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/ecco-jcc\/jjad199","article-title":"Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn\u2019s Disease","volume":"18","author":"Vermeire","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_86","unstructured":"European Medicines Agency (2024, July 24). Skyrizi, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi#product-info."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Danese, S., Beaton, A., Duncan, E.A., Mercier, A.K., Neisen, J., Seth, H., Zetterstrand, S., and Sands, B.E. (2023). Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn\u2019s disease. BMC Gastroenterol., 23.","DOI":"10.1186\/s12876-023-03078-7"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the Treatment of Crohn\u2019s Disease: Induction Results from the Phase 2 GALAXI-1 Study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2174\/1570180820666230726164112","article-title":"Self-assembling Peptides (SAPs) as Powerful Tools for the Preparation of Antimicrobial and Wound-Healing Nanostructures","volume":"21","author":"Dimmito","year":"2024","journal-title":"Lett. Drug Des. Discov."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3748\/wjg.v22.i3.1078","article-title":"Role of antibiotics for treatment of inflammatory bowel disease","volume":"22","author":"Nitzan","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Cai, Z., Wang, S., and Li, J. (2021). Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front. Med., 8.","DOI":"10.3389\/fmed.2021.765474"},{"key":"ref_92","first-page":"592","article-title":"Managing pain in inflammatory bowel disease","volume":"7","author":"Docherty","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.2147\/DDDT.S461977","article-title":"Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment","volume":"18","author":"Gao","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Li, X., Lu, C., Yang, Y., Yu, C., and Rao, Y. (2020). Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease. Biomed. Pharmacother., 129.","DOI":"10.1016\/j.biopha.2020.110486"},{"key":"ref_95","first-page":"10288","article-title":"Multiple lipid nanoparticles as antimicrobial drug delivery systems","volume":"67","author":"Cacciatore","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1023\/A:1011032328064","article-title":"Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa","volume":"18","author":"Lamprecht","year":"2001","journal-title":"Pharm. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jconrel.2014.03.039","article-title":"Budesonide loaded nanoparticles with pHsensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases","volume":"183","author":"Ali","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.nano.2015.02.018","article-title":"Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue","volume":"11","author":"Hua","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jconrel.2012.03.004","article-title":"Nanoparticle-based clodronate delivery mitigates murine experimental colitis","volume":"160","author":"Niebel","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1023\/B:PHAM.0000019298.29561.cd","article-title":"Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes","volume":"21","author":"Jubeh","year":"2004","journal-title":"Pharm. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/ibd\/izz205","article-title":"Nanotechnology in the Treatment of Inflammatory Bowel Disease","volume":"25","author":"Giron","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Mohajeri, S., Moayedi, S., Mohajeri, S., Yadegar, A., and Haririan, I. (2022). Targeting pathophysiological changes using biomaterials-based drug delivery systems: A key to managing inflammatory bowel disease. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1045575"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2174\/1567201818666210609161301","article-title":"Targeted Drug Delivery: Trends and Perspectives","volume":"18","author":"Ashique","year":"2021","journal-title":"Curr. Drug Deliv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2147\/IJN.S291090","article-title":"Dual Functional Eudragit\u00ae S100\/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis","volume":"16","author":"Gao","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"106122","DOI":"10.1016\/j.ejps.2022.106122","article-title":"Preparation and characterization of colon-targeted pH\/Time-dependent nanoparticles using anionic and cationic polymethacrylate polymers","volume":"171","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2174\/1570180820666230214093038","article-title":"Aptamers-based Strategies for the Treatment of Microbial Infections","volume":"21","author":"Marinelli","year":"2024","journal-title":"Lett. Drug Des. Discov."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"10808","DOI":"10.7150\/thno.47601","article-title":"Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy","volume":"10","author":"Wang","year":"2020","journal-title":"Theranostics"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Kim, J.M., Kim, D.H., Park, H.J., Ma, H.W., Park, I.S., Son, M., Ro, S.Y., Hong, S., Han, H.K., and Lim, S.J. (2020). Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model. J. Nanobiotechnology, 18.","DOI":"10.1186\/s12951-020-00693-4"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"136438","DOI":"10.1016\/j.cej.2022.136438","article-title":"Oral administration of inflammatory microenvironment-responsive carrier-free infliximab nanocomplex for the targeted treatment of inflammatory bowel disease","volume":"445","author":"Li","year":"2022","journal-title":"Chem. Eng. J."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Ries, M., Moulari, B., Shetab Boushehri, M.A., Ali, M.E., Molnar, D., B\u00e9duneau, A., Pellequer, Y., and Lamprecht, A. (2022). Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020352"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.actbio.2021.12.015","article-title":"Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease","volume":"140","author":"Shrestha","year":"2022","journal-title":"Acta Biomater."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/9\/1185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:50:17Z","timestamp":1760111417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/9\/1185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":111,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["pharmaceutics16091185"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16091185","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,7]]}}}